

**Reference:** FOI.ICB-2526/189

**Subject:** GP Payments: Injectable ADT & PSA Monitoring (2024/25-2025/26)

*I can confirm that the ICB does hold some of the information requested; please see responses below:*

QUESTION	RESPONSE
<p>1. Copies of all current and previous (since 1 April 2024) service / LES / shared-care specifications, payment schedules, claim forms and templates relating to:</p> <ul style="list-style-type: none"> <li>a. Injectable ADT administration in primary care;</li> <li>b. PSA monitoring / stable prostate cancer follow-up delivered in GP practices.</li> </ul> <p>Clarification received: Please supply the payments to GP practices for injecting the following ADT injections:</p> <p>Staladex 11.25mg Leuprorelin 11.25mg Prostap 11.25mg Zoladex 10.8mg Decapptyl 11.25mg Firmagon 120mg Suprefact 1mg/ml Camcevi 42mg.</p> <p>Please also the Shared Care Agreement Payment the above medications.</p>	<p>a. Shared Care Protocol (SCP): Triptorelin, Goserelin and Leuprorelin, for the Delivery of Gonadotrophin-releasing hormone antagonist (GnRH analogues/ LHRH) treatment, are on our Formulary for prostate cancer indications.</p> <p>There are no current shared care protocols (SCPs) for any of these for prostate cancer indications.</p> <p>We have some SCPs active for breast cancer indications, these are publicly available on the Remedy chapter below: <a href="https://remedy.bnssg.icb.nhs.uk/formulary-adult/chapters/6-endocrine-system/66-gonadotrophin-responsive-conditions/">https://remedy.bnssg.icb.nhs.uk/formulary-adult/chapters/6-endocrine-system/66-gonadotrophin-responsive-conditions/</a></p> <p>Part of the following medications is covered under the Supplementary Services. The Supplementary Services Local Enhanced Service is a basket of services and provides additional funding to general practice for supporting a range of activities and services.</p>

	The ICB does not hold information on individual payments for ADT Injections. The Supplementary Services are paid as a block payment and the funding is not itemised.			
	b. The ICB does not commission PSA monitoring / stable prostate cancer follow-up in GP practices.			
2. The tariffs and payment units for 2024/25 & 2025/26, such as per injection, per PSA test, per review, per patient per quarter/year; any setup or retainer fees; whether drug costs are included or claimed separately.	The ICB does not hold this information.			
3. Coding or template requirements (EMIS/SNOMED etc.) for claims.				
4. All changes to rates since 1 April 2024, with dates.				
5. Activity and spend data for 2024/25: number of injections, PSA tests and clinical reviews paid; total amount paid.	Please see the data from EMIS below. If one of the specified items is missing e.g. Camcevi, then it has not been prescribed (by general practice).			
	Please note: The ICB does not hold the data regarding spend, PSA tests, clinical reviews paid, or total amount paid.			
	Name, Dosage and Quantity	Prescribed quantity	Quantity Unit	Count of prescriptions issued between 1/4/24 and 31/3/25

	Decapeptyl SR 11.25mg powder and solvent for suspension for injection vials (Ipsen Ltd)	1	vial	2599
	Decapeptyl SR 11.25mg powder and solvent for suspension for injection vials (Ipsen Ltd)	2	vial	3
	Decapeptyl SR 11.25mg powder and solvent for suspension for injection vials (Ipsen Ltd)	4	vial	3
	Decapeptyl SR 11.25mg powder and solvent for suspension for injection vials (Ipsen Ltd)	5	vial	2
	Decapeptyl SR 11.25mg powder and solvent for suspension for injection vials (Ipsen Ltd)	9	vial	2

	Leuprorelin 11.25mg implant pre-filled syringes	1	pre-filled disposable injection	20
	Leuprorelin 11.25mg powder and solvent for prolonged-release suspension for injection pre-filled syringes	1	pre-filled disposable injection	178
	Leuprorelin 11.25mg powder and solvent for prolonged-release suspension for injection pre-filled syringes	5	pre-filled disposable injection	1
	Leuprorelin 11.25mg powder and solvent for suspension for injection pre-filled syringes	1	pre-filled disposable injection	900
	Leuprorelin 11.25mg powder and solvent for suspension for injection pre-filled syringes	2	pre-filled disposable injection	4
	Prostap 3 DCS 11.25mg powder and solvent for prolonged-release suspension for injection pre-filled	1	pre-filled disposable injection	368

	syringes (Takeda UK Ltd)			
	Prostap 3 DCS 11.25mg powder and solvent for suspension for injection pre-filled syringes (Takeda UK Ltd)	1	pre-filled disposable injection	1504
	Staladex 11.25mg implant pre-filled syringes (Aspire Pharma Ltd)	1	pre-filled disposable injection	143
	Zoladex LA 10.8mg implant SafeSystem pre-filled syringes (AstraZeneca UK Ltd)	1	pre-filled disposable injection	1137
	Zoladex LA 10.8mg implant SafeSystem pre-filled syringes (AstraZeneca UK Ltd)	2	pre-filled disposable injection	2
	Zoladex LA 10.8mg implant SafeSystem pre-filled syringes (AstraZeneca UK Ltd)	5	pre-filled disposable injection	1

***The information provided in this response is accurate as of 23 October 2025 and has been approved for release by Dr Joanne Medhurst, Chief Medical Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.***